Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial

This RCT (n=90 final analysis) found use of oral valaciclovir (8 g per day, twice daily) reduced vertical transmission of CMV (11% amniocenteses at 21 or 22 weeks positive for CMV versus 30% in the placebo group; OR 0.29, 95% CI 0.09-0.90 p=0.027).


The Lancet